Neuropathic pain (NP) is characterised as a lesion or disease directly affecting the somatosensory system. This study aims to analyse the efficacy of botulinum toxin type A (BT-A) in the treatment of neuropathic pain.
Methods
This systematic literature review, guided by PRISMA, applied the PICO strategy with the following criteria: (P = patients with neuropathic pain, I = botulinum toxin, C = placebo or active drug, and O = pain relief).
Results
Fourteen articles, all randomised controlled trials with a placebo control, were included in the review. A total of 645 patients were randomised, with 353 patients receiving treatment with botulinum toxin type A in doses ranging from 25U to 400U. The evaluated studies addressed trigeminal neuralgia, diabetic polyneuropathy, post-herpetic neuralgia, spinal cord injury, phantom limb pain, and peripheral neuropathic pain after trauma or surgery.
Conclusion
BT-A has emerged as a promising treatment for various origins of neuropathic pain. Therefore, future studies should adopt stricter criteria regarding dosage and routes of administration to ensure effective and consistent BT-A application.
MirandaCCVSeda JuniorLFPellosoLRCA. New physiological classification of pains: current concept of neuropathic pain. Rev Dor. 2016; 17: 2–4. doi:10.5935/1806-0013.20160037.
2.
JensenTSBaronRHaanpääM, et al.A new definition of neuropathic pain. Pain2011; 152: 2204–2205.
3.
BarrosGAMColhadoOCGGiublinML. Clinical presentation and diagnosis of neuropathic pain. Rev Dor. 2016; 17: 15–19. doi:10.5935/1806-0013.20160040.
4.
KraycheteDCGozzaniJLKraycheteAC. Dor neuropática: aspectos neuroquímicos. Rev Bras Anestesiol2008; 58: 492–505.
ParkJParkH. Botulinum toxin for the treatment of neuropathic pain. Toxins2017; 9: 260.
7.
BeneckeR. Clinical relevance of botulinum toxin immunogenicity. BioDrugs2012; 26: e1–e9.
8.
ParkJChungM. Botulinum toxin for central neuropathic pain. Toxins2018; 10: 224.
9.
SousaEJSSousaGCBaiaVF, et al.Botulinum toxin type A in chronic neuropathic pain in refractory leprosy. Arq Neuropsiquiatr2019; 77: 346–351.
10.
PageMJMcKenzieJEBossuytPM, et al.The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ2021: 372: n71.
11.
OuzzaniMHammadyHFedorowiczZ, et al.Rayyan—a web and mobile app for systematic reviews. Syst Rev2016; 5: 210.
12.
HigginsJPTAltmanDGGøtzschePC, et al.The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ2011; 343: d5928.
13.
WuC-JLianY-JZhengY-K, et al.Botulinum toxin type A for the treatment of trigeminal neuralgia: results from a randomized, double-blind, placebo-controlled trial. Cephalalgia2012; 32: 443–450.
14.
ZúñigaCPiedimonteFDíazS, et al.Acute treatment of trigeminal neuralgia with onabotulinum toxin A. Clin Neuropharmacol2013; 36: 146–150.
15.
ZhangHLianYMaY, et al.Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial. J Headache Pain2014; 15: 65.
16.
TaheriMSedaghatMSolhpourA, et al.The Effect of Intradermal Botulinum Toxin a injections on painful diabetic polyneuropathy. Diabetes Metabol Syndr2020; 14: 1823–1828.
17.
ChenW-TYuanR-YChiangS-C, et al.OnabotulinumtoxinA improves tactile and mechanical pain perception in painful diabetic polyneuropathy. Clin J Pain2013; 29: 305–310.
18.
GhasemiMAnsariMBasiriK, et al.The effects of intradermal botulinum toxin type a injections on pain symptoms of patients with diabetic neuropathy. J Res Med Sci2014; 19: 106–111.
19.
SalehiHMoussaeiMKamiabZ, et al.The effects of botulinum toxin type A injection on pain symptoms, quality of life, and sleep quality of patients with diabetic neuropathy: a randomized double-blind clinical trial. Iran J Neurol2019; 18: 99–107.
20.
ShehataHSEl-TamawyMSShalabyNM, et al.Botulinum toxin-type A: could it be an effective treatment option in intractable trigeminal neuralgia?J Headache Pain2013; 14: 92.
21.
ApallaZSotiriouELallasA, et al.Botulinum toxin A in postherpetic neuralgia: a parallel, randomized, double-blind, single-dose, placebo-controlled trial. Clin J Pain2013; 29: 857–864.
22.
XiaoLMackeySHuiH, et al.Subcutaneous injection of botulinum toxin A is beneficial in postherpetic neuralgia. Pain Med2010; 11: 1827–1833.
23.
HanZSongDHOhH, et al.Botulinum toxin type A for neuropathic pain in patients with spinal cord injury. Ann Neurol2016; 79: 569–578.
24.
ChunALevyIYangA, et al.Treatment of at-level spinal cord injury pain with botulinum toxin A. Spinal Cord Ser Cases2019; 5: 77.
25.
AlizadehRTaheriMBeiranvandS, et al.Evaluation of the effectiveness of botulinum toxin injection on reducing phantom pain in patients. Interdiscip Neurosurg2023; 32: 101712.
26.
AttalNde AndradeDCAdamF, et al.Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): a randomised, double-blind, placebo-controlled trial. Lancet Neurol2016; 15: 555–565.
27.
WeiJZhuXYangG, et al.The efficacy and safety of botulinum toxin type A in treatment of trigeminal neuralgia and peripheral neuropathic pain: a meta‐analysis of randomized controlled trials. Brain Behav2019; 9: e01409. DOI: 10.1002/brb3.1409.
28.
HaryVSchitterSMartinezV. Efficacy and safety of botulinum A toxin for the treatment of chronic peripheral neuropathic pain: a systematic review of randomized controlled trials and meta‐analysis. Eur J Pain2022; 26: 980–990.
29.
ColhadoOCGBoeingMOrtegaLB. Botulinum toxin in pain treatment. Rev Bras Anestesiol2009; 59: 366–381.
30.
MorraMEElgebalyAElmaraezyA, et al.Therapeutic efficacy and safety of Botulinum Toxin A Therapy in Trigeminal Neuralgia: a systematic review and meta-analysis of randomized controlled trials. J Headache Pain2016; 17: 63.
31.
BohluliBMotamediMHKBagheriSC, et al.Use of botulinum toxin A for drug-refractory trigeminal neuralgia: preliminary report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod2011; 111: 47–50.
32.
ZúñigaCDíazSPiedimonteF, et al.Beneficial effects of botulinum toxin type A in trigeminal neuralgia. Arq Neuropsiquiatr2008; 66: 500–503.
33.
TürkÜIlhanSAlpR, et al.Botulinum toxin and intractable trigeminal neuralgia. Clin Neuropharmacol2005; 28: 161–162.
34.
KimD-WLeeS-KAhnnJ. Botulinum toxin as a pain killer: players and actions in antinociception. Toxins2015; 7: 2435–2453.
35.
MatakBBach-Rojecky, et al.Mechanisms of botulinum toxin type A action on pain. Toxins2019; 11: 459.
36.
YuanRYSheuJJYuJM, et al.Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology2009; 72: 1473–1478.
37.
LiuH-TTsaiS-KKaoM-C, et al.Botulinum toxin A relieved neuropathic pain in a case of post-herpetic neuralgia. Pain Med2006; 7: 89–91.
38.
SotiriouEApallaZPanagiotidouD, et al.Severe post-herpetic neuralgia successfully treated with botulinum toxin A: three case reports. Acta Derm Venereol2009; 89: 214–215.
39.
PortellaAVTSouzaLCBGomesJMA. Herpes-zóster e neuralgia pós-herpética. Rev Dor2013; 14: 210–215.
LayeequeRHochbergJSiegelE, et al.Botulinum toxin infiltration for pain control after mastectomy and expander reconstruction. Ann Surg2004; 240: 608–613.
42.
FabregatGAsensio-SamperJMPalmisaniS, et al.Subcutaneous botulinum toxin for chronic post-thoracotomy pain. Pain Pract2013; 13: 231–234.
43.
RostamiRMittalSRadmandR, et al.Incobotulinum toxin-A improves post-surgical and post-radiation pain in cancer patients. Toxins2016; 8: 22.
44.
JabbariBMaherNDifazioMP. Botulinum toxin A improved burning pain and allodynia in two patients with spinal cord pathology. Pain Med2003; 4: 206–210.
45.
HanZASongDHChungME. Effect of subcutaneous injection of botulinum toxin A on spinal cord injury-associated neuropathic pain. Spinal Cord2014; 52 Suppl 1: S5–S6.
46.
RanouxDAttalNMorainF, et al.Botulinum toxin type a induces direct analgesic effects in chronic neuropathic pain. Ann Neurol2008; 64: 274–283.
47.
JhangJ-FKuoH-C. Novel treatment of chronic bladder pain syndrome and other pelvic pain disorders by OnabotulinumtoxinA injection. Toxins2015; 7: 2232–2250.
48.
YoonSYOhJ. Neuropathic cancer pain: prevalence, pathophysiology, and management. Korean J Intern Med2018; 33: 1058–1069.
49.
WareJESherbourneCD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care1992; 30: 473–483.
50.
SkevingtonSMLotfyMO’ConnellKA. The World Health Organization’s WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A Report from the WHOQOL Group. Qual Life Res2004; 13: 299–310.
51.
MoonYChoiJParkH, et al.Ultrasound-guided nerve block with botulinum toxin type A for intractable neuropathic pain. Toxins2016; 8: 18.
52.
CarrollIClarkJDMackeyS. Sympathetic block with botulinum toxin to treat complex regional pain syndrome. Ann Neurol2009; 65: 348–351.
53.
KapuralLStillmanMKapuralM, et al.Botulinum toxin occipital nerve block for the treatment of severe occipital neuralgia: a case series. Pain Pract2007; 7: 337–340.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
